Document is current
Any future updates will be listed below
-
Authors
Zhou, Mengyuan https://orcid.org/0000-0002-2078-0767
Gong, Yutian https://orcid.org/0009-0001-9583-0685
Han, Shangrong https://orcid.org/0000-0003-2608-484X
Wang, Meiping
Gu, Wenping
Chen, Hui-Sheng https://orcid.org/0000-0002-7486-1992
Zheng, Wenxu
Feng, Kai
Wang, Dan
Li, Hang https://orcid.org/0000-0003-4543-9271
Zheng, Zhidong
Pan, Yuesong https://orcid.org/0000-0003-3082-6789
Chen, Weiqi https://orcid.org/0000-0002-2551-9314
Wang, Yilong https://orcid.org/0000-0002-3267-0039
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05578521 at ClinicalTrials.govnct05578521 at ClinicalTrials.govDocuments that mention this clinical trial
CerebrAlcare Pills on CereBral Small VesseL DiseasE (CABLE) trial: rationale and design
https://doi.org/10.1136/svn-2024-003756
Documents that mention this clinical trial
CerebrAlcare Pills on CereBral Small VesseL DiseasE (CABLE) trial: rationale and design
https://doi.org/10.1136/svn-2024-003756
-
Funding
Funding for this research was provided by:
Beijing Outstanding Young Scientist Program (BJJWZYJH01201910025030)
Beijing Talent Project (2018A12)
National Natural Science Foundation of China (82425101)
Beijing Laboratory of Oral Health (PXM2021_014226_000041)
Youth Beijing Scholar Program (010)
Key R&D Program of China (2017YFC1307900, 2022YFF1501500, 2022YFF1501501, 2022YFF1501502, 2022YFF1501503, 2022YFF1501504, 2022YFF1501505)
Beijing Municipal Science & Technology Commission (Z231100004823036)
Tasly Pharmaceutical Group Co., Ltd (NA)
Beijing Nova Program (20230484245)
- License Information
